Bucindolol beta blocker targeted to beta receptors in the heart and vasculature: Subsidiary Intercardia Inc. began a Phase III trial in up to 2,800 patients, wi

Interneuron Pharmaceuticals (IPIC), Lexington, Mass. Product: Bucindolol beta blocker targeted to beta receptors in the heart and vasculature Indication: Congestive heart failure Status: Subsidiary I...